Breast cancer survival by teaching status of the initial treating hospital

Ruhee Chaudhry,* Vivek Goel,† Carol Sawka‡

Abstract

Background: A number of studies have documented variation in treatment patterns by treatment setting or by region. In order to better understand how treatment setting might affect survival, we compared the survival outcomes of women with node-negative breast cancer who were initially treated at teaching hospitals with those of women initially treated at community hospitals.

Methods: We constructed a retrospective cohort consisting of a random sample of 938 cases, initially diagnosed in 1991, drawn from the Ontario Cancer Registry. Exposure was defined by the type of hospital in which the initial breast cancer surgery was performed. Outcomes were ascertained through follow-up of vital statistics.

Results: The crude 5-year survival rate was 88.7% for women who had their initial surgery in a community hospital and 92.5% for women who had their initial surgery in a teaching hospital. Women in higher income neighbourhoods experienced better survival at 5 years regardless of which type of hospital they were treated in. Multivariate proportional hazards regression modelling demonstrated a 53% relative reduction in risk of death among women with tumours less than or equal to 20 mm in diameter who were treated at a teaching hospital (relative risk [RR] = 0.47, 95% confidence interval [CI] 0.23–0.96), whereas among those with larger tumours there was no demonstrated difference in survival (RR = 1.32, 95% CI 0.73–2.32). Other variables that were significant in the model were age at diagnosis, estrogen receptor status and the use of radiation therapy.

Interpretation: Women with node-negative breast cancer and tumours less than or equal to 20 mm in diameter who were initially seen at a teaching hospital had significantly better survival than women with similar tumours who were initially seen at a community hospital. Survival among women with larger tumours was not statistically significantly different for the 2 types of hospital.

Many studies have demonstrated variation in treatment for breast cancer across regions and populations. These variations include different patterns of initial breast surgery,1,2 use of chemotherapy,1 hormone therapy3 and radiation therapy.5,6 Characteristics of both patients and care providers have been related to these variations. One key factor that has been considered is the teaching or academic status of both the treating physician and the institution where care is provided. A major point of contention is whether these variations are related to differences in outcomes.

Variations in care may lead to different outcomes through different access to services or different use of proven therapies. Certain physicians may acquire greater skills through frequently dealing with certain types of case, as has been suggested in studies of the volume–outcome relationship.7 Teaching status may affect patient outcomes directly because of better knowledge and skills or indirectly as a result of improved processes of care, such as the use of multidisciplinary clinics. Breast cancer survival has been shown to vary by region and socio-economic status,8–10 as well as by hospital and physician characteristics.11–16

We located 6 published studies examining the relationship between hospital or surgeon characteristics and breast cancer survival. Of these, 4 considered hospital size or teaching status11–13,16 and 2 considered surgeon specialization.14,15 Five of the 6 studies demonstrate better survival where initial surgery was performed at large or specialized centres. All but one of these studies17 have been synthesized in a review...
by Grilli and colleagues, who report a significant pooled odds ratio of 0.82 (95% confidence interval [CI] 0.77–0.88), showing a reduction in risk of death. The cohorts for these studies were constructed over a period of 6–11 years prior to 1990. Treatment information was available for only 3 of the 6 studies, and not all were able to control for stage of disease.

This study compares the 5-year survival of women with node-negative breast cancer who received initial surgical treatment in teaching hospitals with those treated in non-teaching hospitals, while controlling for potential confounders. Because the cohort we examined is composed of women diagnosed in the same year with well-defined localized cancer, variation in stage is unlikely to play a role in our findings.

Methods

We conducted a retrospective, population-based, cohort study by identifying cases of node-negative breast cancer that were newly diagnosed in 1991 in Ontario. This study is based on an earlier study that compared patterns of practice for breast cancer in 2 Canadian provinces. The Ontario Cancer Registry, which has been shown to have a high level of coverage, was used to select cases. Because the cancer registry does not contain detailed information on cancer stage, the records of all cases that met the basic inclusion criteria were further reviewed to assess eligibility for the study.

The basic inclusion criterion was that nodal status was confirmed to be negative by pathologic examination. Patients for whom management was more likely to be complex or who were less likely to receive standard treatments were excluded. Patients thus excluded were those over 90 years of age, those whose breast cancer was diagnosed by death certificate only or who died within 30 days of diagnosis, those with nonepithelial forms of cancer, those with previous invasive cancer or breast carcinoma in situ, those with tumours extending to the chest wall or skin, and those with bilateral breast cancer or carcinoma in situ. Cases in which initial treatment was provided out of province were also excluded. Because the cohort is composed of women diagnosed in 1991 in Ontario. This study is based on an earlier study that compared patterns of practice for breast cancer in 2 Canadian provinces. The Ontario Cancer Registry, which has been shown to have a high level of coverage, was used to select cases. Because the cancer registry does not contain detailed information on cancer stage, the records of all cases that met the basic inclusion criteria were further reviewed to assess eligibility for the study.

The main outcome, survival after breast cancer, was assessed by linking the cohort back to the Ontario Cancer Registry. The registry receives copies of mortality data based on death registrations from the Ontario Registrar General. In addition, the registry links data about death notifications from cancer centres and in-hospital deaths of patients who had a cancer diagnosis. The current analysis was based on mortality records through to Dec. 31, 1996. Cause of death was assessed and coded using the International Classification of Diseases, ninth revision, based on information on the death certificate. The death certificates were reviewed for all subjects in the cohort known to have died in order to ascertain the recorded principal and contributing causes of death and to verify the primary cause.

Descriptive statistics were used to compare the case mix of women initially treated at teaching hospitals versus community hospitals. Kaplan-Meier survival curves and the Cox proportional hazards model were used to assess the relationship between individual explanatory variables and survival outcomes. A multivariate proportional hazards regression model was developed, initially grouping variables by patient, tumour, treatment and provider characteristics. Interactions between each of the significant variables and the main exposure, teaching status, were assessed. Survival time was calculated as the time between date of diagnosis and date of death.

Results

The final cohort was composed of 938 women diag-
nosed with breast cancer in 1991. Of these women, 292 (31%) had had their initial surgery at a teaching hospital. Table 1 summarizes the characteristics of these women by initial treating hospital. The 2 populations were similar with respect to distribution by socio-economic status (median neighbourhood family income) and proportion living in urban residences. Neighbourhood income was divided based on the median value; however, using other cutoff points did not change the results. Distance to the nearest radiation treatment facility, which was also used as means of considering issues of accessibility, did not provide additional information.

Women seen in teaching hospitals were significantly younger, had smaller tumours and were more likely to be diagnosed with multifocal disease and extensive ductal carcinoma in situ. Information about tumour grade was more likely to be missing for women seen in community hospitals. However, data about estrogen receptor status were missing more often for women seen at teaching hospitals, which is contrary to information reported in other studies.

The proportion of women receiving different modes of therapy is shown in Table 2. Women seen in teaching hospitals were significantly more likely to receive BCS and adjuvant therapy, and they had a greater number of lymph nodes examined. They were less likely to be treated with surgery alone.

The crude 5-year survival rate was 88.7% for women having initial surgery in a community hospital and 92.5% for women with initial surgery in a teaching hospital ($p = 0.07$). Women in higher income neighborhoods experienced better survival at 5 years whether they were treated at community or teaching hospitals (Table 3). Fig. 1 shows the 5-year Kaplan-Meier survival curves stratified by hospital type.

The results of proportional hazards regression modelling are presented in Table 4. Modelling the effect of hospital type on its own showed a 33% reduction in risk for women seen at teaching hospitals (relative risk [RR] = 0.67, 95% CI 0.53–1.03). In the multivariate model, a significant interaction was noted between size of tumour and the type of hospital at which initial surgery was performed. Women with tumours less than or equal to 20 mm in diameter experienced a 53% reduction in risk of death (RR = 0.47, 95% CI 0.29–0.73).
95% CI 0.23–0.96) if initial surgery was carried out in a teaching hospital, whereas no difference was found among those with larger tumours (RR = 1.32, 95% CI 0.73–2.32). The effect of hospital type on survival did not vary greatly with the introduction or removal of treatment variables.

The power for disease-specific analysis was quite limited (Table 1). Multivariate modelling of breast cancer deaths alone did not show any a significant difference in survival (RR = 0.74, 95% CI 0.41–1.32).

**Interpretation**

This study demonstrates a survival advantage for women with small tumours who underwent initial surgery at a teaching hospital. Although this advantage appears small in absolute terms, it is comparable to that observed for adjuvant systemic therapy. The difference is not explained by patient characteristics, such as age or socio-economic status, disease stage or treatment variables. Accounting for patient case mix increased the difference in survival.

There are several possible explanations for our results. First, there may be differences in the 2 patient populations in terms of characteristics not controlled for in the analysis. There may be different patterns of use of early detection and other diagnostic tests among women who seek treatment at different facilities. For example, women with non-palpable tumours detected by mammography, which tend to be smaller and localized, were perhaps more likely to be seen at teaching facilities. Data on screen-detected versus clinically detected tumours were not available to enable finer analysis. There may also be variable referral patterns. However, one would generally expect surgeons in teaching hospitals to receive more complex cases, which may explain the finding that there is no difference in survival for women with larger tumours. On the other hand, women who ask to be or are referred to a teaching hospital, or seek out an academic surgeon, may be in generally better health or have healthier behaviours, resulting in improved survival. Very few of the women in our cohort (2%) were enrolled in clinical trials.

Another possible explanation may be that what is being observed is an artifact of misclassification of cases by disease stage. There were fewer numbers of nodes examined in community hospital cases, which might have led some women with node-positive disease to be misclassified as

### Table 3: Crude 5-year survival estimates

<table>
<thead>
<tr>
<th>Stratification variable</th>
<th>Community hospital</th>
<th>Teaching hospital</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hospital type</td>
<td>88.7 (86.3–99.1)</td>
<td>92.5 (89.4–95.5)</td>
</tr>
<tr>
<td>Median neighbourhood family income, $</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt; 45 000</td>
<td>87.8 (84.3–91.3)</td>
<td>89.9 (95.3–94.6)</td>
</tr>
<tr>
<td>≥ 45 000</td>
<td>89.6 (86.2–93.0)</td>
<td>95.4 (92.0–99.0)</td>
</tr>
<tr>
<td>Tumour size, mm</td>
<td></td>
<td></td>
</tr>
<tr>
<td>≤ 20</td>
<td>90.6 (87.9–93.3)</td>
<td>95.7 (93.0–98.5)</td>
</tr>
<tr>
<td>&gt; 20</td>
<td>84.3 (79.3–89.3)</td>
<td>83.1 (74.7–91.5)</td>
</tr>
</tbody>
</table>

**Fig. 1: Kaplan-Meier survival curves for patients by type of hospital at which initial surgery for breast cancer was performed.**
node-negative. However, whereas the mean number of nodes examined in the community hospital was lower than that examined in teaching hospitals, it was still high (9.2), making this explanation unlikely. A more subtle bias may have arisen if there were systematic differences in the use of nodal dissection across the 2 types of hospital, given that women with unassessed nodal status were excluded from the study. For example, if community hospitals were more likely to forgo nodal dissections in some cases of clearly localized disease or, conversely, if teaching hospitals were more likely to forgo nodal dissections in cases of more advanced disease, the 2 cohorts would not be as comparable as has been thought. Although it is more likely that nodal dissections would have been forgone in women with more advanced disease, there is no reason to expect evidence to suggest that this would be more likely in teaching hospitals than in community hospitals.

Finally, there may indeed have been subtle differences in the processes of care in the 2 types of hospital, leading to different outcomes. This could include greater use of multidisciplinary teams in the teaching hospitals, with more appropriate use of adjuvant therapy, closer surveillance in follow-up, with a reduction in the number and severity of recurrences, and improved supportive care. Resources available in the teaching hospitals, such as access to specialized breast pathology, may also play a role. This may be reflected in the differences in assessment of tumour grade or estrogen receptors between teaching and community hospitals.

Although the role and skills of the surgeon may be important factors in outcomes for many surgical procedures, they are less likely to be the explanations here. First, breast surgery procedures are not as complex as other procedures where volume–outcome relationships have been observed. Second, we have observed long-term outcomes from breast cancer, and the characteristics of the surgery itself play only a small part in determining the outcome.

There are several notable limitations to this study. The number of events was small, limiting the study’s power. The classification of exposure was done post hoc in a retrospective study. However, it would be difficult to evaluate this hypothesis using an experimental design. We had limited information on comorbidities and other health behaviours that may have affected survival. Finally, there was some missing information on tumour characteristics that may not have been random across the 2 populations.

In conclusion, this study suggests that treatment at teaching centres may be advantageous for women with small tumours. There is a need to identify whether these results can be attributed to differences in specific processes of care. If this is indeed the case, then these processes could be applied in community settings.

Competing interests: None declared.

Contributors: Ms. Chaudhry was the principal author and completed this analysis as part of her MSc degree. She was involved in the data linkage between the original cohort and the mortality data, the review of death certificates, analysis of data and the preparation of the manuscript. Drs. Goel and Sawka were coauthors and coprincipal investigators in the assembly of the cohort of Ontario breast cancer patients, they were responsible for the collection of data about the cohort, and they supervised data linkage and analysis and the preparation of the manuscript. Dr. Goel was Ms. Chaudhry’s thesis supervisor and Dr. Sawka was a member of her thesis committee.

Acknowledgements: The assistance of the staff of the Ontario Cancer Registry, Cancer Care Ontario, is warmly acknowledged. The development of the original cohort was supported by a grant from the National Cancer Institute of Canada.

References


12. Basnet I, Gill M, Tobias JS. Variations in breast cancer management be-
How you can get involved in the CMA!

The CMA is committed to providing leadership for physicians and promoting the highest standard of health and health care for Canadians. To strengthen the Association and be truly representative of all Canadian physicians, the CMA needs to hear from members interested in serving in elected positions and on appointed committees and advisory groups.

The CMA structure comprises both governing bodies and advisory bodies either elected by General Council or appointed by the CMA Board of Directors. The Board of Directors - elected by General Council - has divisional, affiliate, resident and student representation, is responsible for the overall operation of the CMA and reports to General Council on issues of governance. CMA councils and committees advise the Board of Directors and make recommendations on specific issues of concern to physicians and the public. Four core councils and committees consist of either divisional or regional representation while other statutory and special committees, expert working and project advisory groups comprise individuals with interest and expertise in subject-specific fields. Positions on one or more of these committees may become available in the coming year.

For further information on how you can get involved, please contact:

Patricia Trunzo
Core Advisory Services Officer, Corporate Affairs
Canadian Medical Association
1867 Alta Vista Drive
Ottawa, ON K1G 3Y6
Fax: (613) 326-7570
Tel. 1-800-663-7336, ext. 1113
Email: trunzp@cma.ca

By getting involved, you will have an opportunity to make a difference.

We hope to hear from you.

Comment vous pouvez participer à l’AMC!

L’AMC est vouée à jouer un rôle de chef de file auprès des médecins et à promouvoir les normes les plus élevées de santé et de soins de santé pour les Canadiens. Afin de renforcer l’Association et pour qu’elle représente véritablement tous les médecins du Canada, l’AMC a besoin de membres intéressés à occuper des charges élues et à siéger à des comités et des groupes consultatifs.

La structure de l’AMC est composée d’organes de régie élus par le Conseil général et d’entités consultatives nommées par le Conseil d’administration. Le CA, dont les membres sont élus par le Conseil général, réunit des représentants des divisions, des sociétés affiliées, des résidents et des étudiants en médecine et est chargé de l’administration générale de l’AMC. Il rend compte de questions de régie au Conseil général. Les conseils et les comités de l’AMC jouent le rôle de conseillers auprès du Conseil d’administration et présentent les recommandations au sujet de questions particulières qui intéressent les médecins et la population. Quatre conseils et comités principaux sont constitués de représentants des divisions et des régions, tandis que les autres comités statutaires et spéciaux, les groupes d’experts et les groupes consultatifs de projets réunissent des personnes qui s’intéressent à des sujets précis et possèdent des compétences spécialisées. Des postes pourront devenir vacants dans un ou plusieurs de ces comités en cours d’année.

Pour en savoir davantage sur les modalités de participation, veuillez communiquer avec

Patricia Trunzo
Agente, Services aux structures consultatives, Affaires générales
Association médicale canadienne
1867, promenade Alta Vista
Ottawa (Ontario) K1G 3Y6
Téléc. : (613) 526-7570
Tél. : 1-800-663-7336, poste 1113
Courriel : trunzp@cma.ca

Votre participation peut faire la différence.

Nous espérons avoir de vos nouvelles!